Loading clinical trials...
Loading clinical trials...
A Phase 1/2 Study Evaluating the Safety and Efficacy of Anti-CD19 Chimeric Antigen Receptor-Modified T Cell (CAR-T) Therapy Bridging to Hematological Stem Cell Transplantation (HSCT) for Relapsed/Refractory CD19+ B-Cell Malignancies
Conditions
Interventions
Allogeneic hematological stem cell transplantation
Locations
1
China
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China
Start Date
April 15, 2016
Primary Completion Date
January 1, 2021
Completion Date
June 1, 2021
Last Updated
May 10, 2019
NCT05376111
NCT05006716
NCT04065399
NCT06026319
NCT05453500
NCT07295951
Lead Sponsor
Wuhan Sian Medical Technology Co., Ltd
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions